Array BioPharma Inc. (ARRY) EPS Estimated At $-0.24; 24 Analysts Are Bullish Vertex Pharmaceuticals (VRTX) Last Week

January 13, 2018 - By Michael Collier

Analysts expect Array BioPharma Inc. (NASDAQ:ARRY) to report $-0.24 EPS on February, 8.They anticipate $0.10 EPS change or 71.43% from last quarter’s $-0.14 EPS. After having $-0.22 EPS previously, Array BioPharma Inc.’s analysts see 9.09% EPS growth. The stock decreased 1.72% or $0.24 during the last trading session, reaching $13.71. About 2.98 million shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 176.51% since January 13, 2017 and is uptrending. It has outperformed by 159.81% the S&P500.

Among 28 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 24 have Buy rating, 0 Sell and 4 Hold. Therefore 86% are positive. Vertex Pharmaceuticals had 81 analyst reports since July 31, 2015 according to SRatingsIntel. On Tuesday, September 1 the stock rating was upgraded by Vetr to “Buy”. As per Tuesday, December 12, the company rating was maintained by JMP Securities. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Wednesday, March 1 by Citigroup. Leerink Swann maintained it with “Buy” rating and $187.0 target in Tuesday, September 26 report. The rating was maintained by Cowen & Co on Wednesday, July 5 with “Hold”. H.C. Wainwright upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Friday, October 30 to “Buy” rating. Cowen & Co maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, September 25 with “Buy” rating. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Wednesday, October 18 by RBC Capital Markets. The firm has “Neutral” rating given on Monday, October 24 by H.C. Wainwright. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Robert W. Baird on Wednesday, September 6. See Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) latest ratings:

05/01/2018 Broker: Bank of America Rating: Buy New Target: $180.0 Upgrade
02/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $184.0 Maintain
13/12/2017 Broker: Deutsche Bank Rating: Buy New Target: $175 Initiates Coverage On
12/12/2017 Broker: JMP Securities Rating: Buy New Target: $200.0 Maintain
26/10/2017 Broker: Needham Rating: Buy New Target: $195.0 Maintain
26/10/2017 Broker: Jefferies Rating: Buy New Target: $185.0 Maintain
26/10/2017 Broker: H.C. Wainwright Rating: Hold New Target: $85.0 Maintain
26/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $205.0 Maintain
20/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $189.0 Maintain
18/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $181.0 Maintain

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $2.70 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

Among 10 analysts covering Array BioPharma (NASDAQ:ARRY), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Array BioPharma had 29 analyst reports since June 3, 2016 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, August 9. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Wednesday, September 20 by Piper Jaffray. SunTrust initiated Array BioPharma Inc. (NASDAQ:ARRY) on Friday, June 3 with “Buy” rating. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Stifel Nicolaus on Friday, February 3. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, October 31. The stock has “Mkt Perform” rating by Leerink Swann on Monday, January 30. The company was maintained on Thursday, July 13 by Jefferies. The company was maintained on Tuesday, October 31 by SunTrust. The rating was maintained by Cowen & Co on Tuesday, October 31 with “Buy”. The rating was maintained by Piper Jaffray with “Buy” on Friday, September 8.

Investors sentiment increased to 1.21 in Q3 2017. Its up 0.05, from 1.16 in 2017Q2. It is positive, as 34 investors sold Array BioPharma Inc. shares while 43 reduced holdings. 41 funds opened positions while 52 raised stakes. 190.80 million shares or 15.63% more from 165.02 million shares in 2017Q2 were reported. Nationwide Fund Advisors holds 0.02% or 380,713 shares. Baker Bros Limited Partnership holds 5.21 million shares or 0.52% of its portfolio. Alps, Colorado-based fund reported 168,843 shares. 2.97 million were reported by Pinnacle Associate Limited. Knott David M holds 0.04% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY) for 6,900 shares. State Of New Jersey Common Pension Fund D, a New Jersey-based fund reported 265,000 shares. Next Fin Gru owns 1,490 shares for 0.01% of their portfolio. Jnba Fincl Advisors invested in 500 shares or 0% of the stock. Point72 Asset Management Lp has invested 0.49% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Pointstate Lp reported 0.2% stake. Credit Agricole S A invested 0% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Eam Lc has invested 0.33% in Array BioPharma Inc. (NASDAQ:ARRY). 343,559 are held by Balyasny Asset Management Limited Liability. North Star Invest Mgmt stated it has 0.08% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Macquarie Group Incorporated stated it has 0.01% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY).

Since September 29, 2017, it had 0 insider purchases, and 4 insider sales for $12.91 million activity. $3.03 million worth of Array BioPharma Inc. (NASDAQ:ARRY) was sold by Robbins Andrew R. Squarer Ron sold $8.90M worth of stock. Shares for $493,510 were sold by VAN LUNSEN GIL J. LEFKOFF KYLE sold $478,428 worth of stock.

The stock decreased 0.30% or $0.47 during the last trading session, reaching $157.93. About 1.56M shares traded or 1.87% up from the average. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since January 13, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Since July 31, 2017, it had 0 insider purchases, and 23 sales for $64.38 million activity. Chodakewitz Jeffrey sold $521,895 worth of stock. 860 shares valued at $131,571 were sold by Silva Paul M on Monday, July 31. SMITH IAN F also sold $660,415 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. LEIDEN JEFFREY M also sold $17.67M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. Parini Michael had sold 2,330 shares worth $362,828. On Thursday, August 3 Arbuckle Stuart A sold $661,810 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 4,250 shares. $1.68M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Bhatia Sangeeta N..

Investors sentiment increased to 1.62 in Q3 2017. Its up 0.11, from 1.51 in 2017Q2. It increased, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. 254 were reported by Tarbox Family Office. Old Mutual Customised Solutions (Proprietary) owns 7,526 shares for 0.16% of their portfolio. New York-based Eulav Asset Mngmt has invested 0.9% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). San Francisco Sentry Invest Grp Inc (Ca) reported 212 shares. 202,372 are owned by British Columbia Management. Tocqueville Asset Management Ltd Partnership has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Ls Investment Advsrs Ltd Co reported 0.06% stake. Atwood Palmer Inc stated it has 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 834,257 were accumulated by Morgan Stanley. Walleye Trading Ltd Limited Liability Company owns 3,502 shares or 0% of their US portfolio. Green Valley Invsts Llc invested in 0.96% or 129,744 shares. Hillsdale Invest accumulated 0.07% or 2,820 shares. Parkside Bancorp has 0.02% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Bb&T Securities Lc stated it has 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Keybank National Association Oh owns 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 4,514 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com